Skip to main content
Article thumbnail
Location of Repository

Beneficial Effect of Food Substitute Containing L-Arginine, ω-3 Poly Unsaturated Fatty Acid, and Ribonucleic Acid in Preventing or Improving Metabolic Syndrome: A Study in 15 Overweight Patients and a Study of Fatty Acid Metabolism in Animals

By Kenichi Watanabe, Wawaimuli Arozal, Hiroko Tanaka, Meilei Ma, Susumu Satoh, Punniyakoti T. Veeraveedu, Takashi Kobayashi, Hiroshi Oyama and Yoshiko Sakaguchi

Abstract

This study was conducted to investigate whether or not a food substitute (Dr. BAANs®) containing three bioactive components L-arginine, ω-3 polyunsaturated fatty acid, and ribonucleic acid, supplied orally to 15 overweight patients, may have efficacy to prevent or improve the metabolic syndrome of these patients. To provide supporting data for this clinical study, the in vivo fatty acid metabolism of obese mice was analyzed using 125I labeled 15-(p-iodophenyl)-9-methylpentadecanoic acid (9MPA) in the tissues’ lipid pool. After 3 months of intervention, the results showed that there were improvements observed in liver functions, lipid profiles and metabolic syndrome marker. Significant differences were also found in the values of blood pressure, body weight, percentage of body fat, and body mass index. In the animal study, the tissue uptake of 125I-9MPA at 10 min after injection was higher in obese mice than in the control mice and the treatment with Dr. BAANs® in obese mice decreased the uptake significantly. The final product metabolite of p-iodophenylacetic acid in obese mice was increased significantly by the treatment. In conclusion, this food substitute may have a beneficial effect for the prevention or improvement of metabolic syndrome

Topics: Original Article
Publisher: the Society for Free Radical Research Japan
OAI identifier: oai:pubmedcentral.nih.gov:2675026
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1957). A simple method for the isolation and purification of total lipids from animal tissues.
    2. (2007). Abdominal irradiation ameliorates obesity in ob/ob mice.
    3. (2007). Adiponectin independently predicts metabolic syndrome in overweight latino youth.
    4. (2000). Arginine nutrition and cardiovascular function.
    5. (2005). arginine supplementation reduces fat mass in Zucker diabetic fatty rats.
    6. (2006). Beneficial effects of a long-term oral L-arginine treatment added to a hypo caloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients.
    7. (2004). Clinical management of metabolic syndrome.
    8. (2000). Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferators-activated receptor α associated with agedependent cardiac toxicity.
    9. (2015). Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. Diabetes Care,
    10. (2004). Effect of ribose supplementation on resynthesis of adenine nucleotides after intense intermittent training in humans.
    11. (2005). Evaluation of fatty acid metabolism in hearts after ischemia-reperfusion injury using a dual isotope autoradiographic approach and tissue assay for metabolites of tracer.
    12. (2006). exercise and the metabolic syndrome.
    13. (2003). Fish consumption, fish oil, omega3 fatty acids, and cardiovascular disease.
    14. (2002). for the Study of Obesity: The examination committee of criteria for ‘obesity disease’ in Japan: New criteria for ‘obesity disease’ in Japan.
    15. (2004). L-arginine and hypertension.
    16. (2004). Leptin and proinflammatory state associated with human obesity.
    17. (2007). Metabolic syndrome.
    18. (2006). n-3 fatty acids and the metabolic syndrome.
    19. (2006). New novel food and metabolic syndrome.
    20. (2006). Nucleotide supplementation: a randomized double-blind placebo controlled trial of IntestAidlB in people with irritable bowel syndrome [ISRCTN67764449].
    21. (2004). Obesity, metabolic syndrome, and cardiovascular disease.
    22. (2006). PAI-1 and the metabolic syndrome.
    23. (2005). Prevalence of metabolic syndrome in a 22,892 Japanese population and its associated with life style.
    24. (2003). Relationship of metabolic syndrome and fibrinolytic dysfunction to cardio vascular disease.
    25. (2007). The role of consumption of alpha-linolenic, eicosanpentaenoic and docosanhexaenoic acids in human metabolic syndrome and type 2 diabetes—a mini review.
    26. (2003). The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC report.
    27. (2006). Treatment and prevention of obesity—are there critical periods for intervention?

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.